English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 855307      Online Users : 1020
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/7540


    Title: STMN1 overexpression as a poor prognostic factor in patients with Nasopharyngeal Carcinoma
    Authors: Lee, S;Lin, L;Shiue, Y;Lin, C
    Contributors: National Institute of Cancer Research
    Abstract: Purpose/Objective(s): Despite the advances in diagnostic imaging and treatment modalities, the risk stratification and final outcomes in patients with nasopharyngeal carcinomas (NPC) still remain suboptimal. Through data mining from published transcriptomic database, STMN1 was first identified as a differentially upregulated gene in NPC tissues, which encodes stathmin implicating cell division via regulation of the microtubule filament system. Given the roles of STMN1 expression in NPC has not been systemic evaluated; we explored the significance of STMN1 immunoexpression status in a well-defined cohort of NPC patients. Materials/Methods: STMN1 immunohistochemistry was retrospectively performed and analyzed using H-score method for biopsy specimens from 124 NPC patients who received standard treatment without distant metastasis at initial diagnosis. Those cases with H-score larger than the median value were construed as featuring STMN1 overexpression. The results were correlated with the clinicopathological variables, diseasespecific survival (DSS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRFS). Results: STMN1 overexpression was significantly associated with primary tumor status (p Z 0.003) and AJCC stages III-IV (p Z 0.006) and univariately predictive of adverse outcomes for DSS (pZ0.0001), DMFS (p Z 0.0004), and LRFS (p Z 0.0009). In multivariate comparisons, STMN1 overexpression still remained prognostically independent to portend worse DSS (pZ0.001, hazard ratioZ2.530), DMFS (pZ0.003, hazard ratio Z 2.541), and LRFS (p Z 0.006, hazard ratio Z 2.660) together with advanced AJCC stages III-IV. Conclusions: STMN1 expression is upregulated in a subset of NPCs and its increased immunoexpression significantly correlated with advanced stages and tumor aggressiveness, justifying the potentiality of STMN1 as a prognostic biomarker and a novel therapeutic target of NPC.
    Date: 2013-10
    Relation: International Journal of Radiation Oncology Biology Physics. 2013 Oct;87(2, Supple. 1):S666-S667.
    Link to: http://dx.doi.org/10.1016/j.ijrobp.2013.06.1766
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0360-3016&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000324503602412
    Appears in Collections:[其他] 會議論文/會議摘要

    Files in This Item:

    File Description SizeFormat
    SDO036030161302436X.pdf51KbAdobe PDF481View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback